A phase 3 trial showed that Imfinzi in combination with chemotherapy reduced the risk of death by 20% compared with chemotherapy alone.
Formulary Watch
Latest News
All News
Advertisement
Konvomep, an oral liquid of omeprazole and sodium bicarbonate, will be available in the first quarter of 2023
With this approval, about 300 children between 12 months and 24 months will be eligible for treatment with Orkambi.
HHS is providing $11 million to Grand River Aseptic Manufacturing to accelerate manufacturing of the Jynneos monkeypox vaccine. The facility will be operational later this year.
Spevigo is a monoclonal antibody that inhibits interleukin-36 (IL-36) signaling approved to treat for adults with generalized pustular psoriasis flares.
This application is for a new formulation of carbidopa/levodopa extended-release capsules to treat patients with Parkinson’s disease.
Xenpozyme, the first disease-specific treatment for acid sphingomyelinase deficiency (ASMD), is expected to be available in the United States in the coming weeks at a wholesale acquisition cost of $7,142 per vial.
PSG’s latest Artemetrx specialty spend report finds that, as with 2020, claim utilization continues to drive the trend.
Labor shortages and Drug Enforcement Agency quotas have led to supply shortages of Adderall and its generics, which are used to treat attention deficit hyperactivity disorder.
Ryaltris is a fixed-dose combination therapy that provides relief for both nasal and ocular symptoms of seasonal allergic rhinitis in a nasal spray.
Advertisement
The approval of the updated bivalent boosters is based on data from clinical studies of the omicron variant BA.1, and animal data on the omicron BA.4 and BA.5 variant.
This recall of propofol because of particulates seen in vials follows a previous one in July 2022.
The direct-to-consumer pharmacy also added 13 new products, and now carries almost 1,000 medications.
The target action date for the agency’s decision for efanesoctocog alfa, a factor VIII therapy, is Feb. 28, 2023.
Survey participants said their drug costs have gone up and almost a third had trouble paying for food and housing because of high drug costs.
Hyftor was approved in April 2022 to treat patients with the rare disease facial angiofibroma associated with tuberous sclerosis complex.
Payer coverage and the prior authorization process continue to be barriers for the adoption of biosimilars, according to a new Vizient survey.
Pemazyre is the first approved treatment specifically for patients with FGFR1 rearrangement, a rare blood cancer.
Imbruvica is the first approved treatment option for children under 12 with chronic graft versus host disease and the first BTKi therapy approved for pediatric patients.
The PBM is removing four products and adding one product back to its standard control formulary.
Pending authorization, Moderna will be ready to ship the updated bivalent booster in September 2022.
Out-of-pocket costs decreased for those with insurance but rose for those without insurance, finds RAND study.
The FDA has assigned a Prescription Drug User Fee Act action date of June 16, 2023.
Omnipod 5 is now available through retail pharmacies, as well as specialty and mail-order pharmacies.
The updated COVID-19 vaccine booster specifically addresses the omicron BA.4/BA.5 variants. If authorized, it will be available to ship immediately.
Novavax’s vaccine is the first protein-based COVID-19 vaccine authorized in the United States.
Advertisement
Advertisement
